ACPC Quality Network

22q11 Testing in Tetralogy of Fallot

ACPC QNet
December 7, 2016

» Susan Saleeb, MD – Boston Children’s Hospital
» Tess Saarel, MD – Cleveland Clinic
» Rukmini Komarlu, MD - Cleveland Clinic
The Metric: 22q11.2 Testing in Tetralogy of Fallot

- Number of patients ≤ 18 yoa with Tetralogy of Fallot (TOF), who have undergone/ been ordered for 22q11.2 deletion testing

- Exclusions:
  - More complex forms of TOF
    - TOF/AV canal
    - TOF/pulmonary atresia with MAPCAS
    - TOF/absent pulmonary valve
  - Other genetic disorders
    - Trisomy 21, 13, 18
    - Alagille syndrome
Why Test for 22q11.2 in TOF?

- TOF patients can have significant genetic findings in up to **25% of cases**
  - Trisomy 21, 13, or 18, and Alagille syndrome
  - 22q11.2 deletion present in:
    - 15% of all TOF patients
    - 6% with left aortic arch with normal branching

- Knowledge of 22q11.2 deletion can impact:
  - Clinical management
  - Counseling
Why Test for 22q11.2 in TOF?

- Impact on care with knowledge of 22q11:
  - Neurocognitive
  - Feeding difficulties
    - Palate
    - Motility
  - Immune deficiency
  - Endocrine:
    - Parathyroid - calcium regulation
    - Thyroid
  - Thrombocytopenia
  - Renal anomalies
  - Psychiatric disease
  - Genetic counseling – autosomal dominant
What has the data shown so far?

Proportion of Tetralogy of Fallot (ToF) patients who received a test for 22q11.2 deletion.

Q4 2015

- 17%
- 45%
- 60%
- 60%

Q1 2016

- 100%
- 75%
- 50%
- 53%
- 55%
- 60%

Q2 2016

- 100%
- 15%
- 25%
- 55%
- 65%
- 72%
- 72%
- 75%
- 75%
- 75%
Why is Testing for 22q11.2 so Variable?

- **Practice variation**
  - Only ordered if suspected versus in all
  - Cardiology versus genetics

- **Difficulty in data capture**
  - Genetic testing sent prenatally
  - Genetic testing sent from hospital of birth

- **Variable documentation of data**
  - Consistent location in medical record
  - Record even if normal
22q11 Screening in TOF: KEY DRIVER DIAGRAM

SMART AIM

Increase screening for 22q11 deletion in patients with TOF to 100% at all QNet participating pediatric heart centers by December 31, 2017

GLOBAL AIM

To provide appropriate counseling, multidisciplinary care, and early intervention services for patients with 22q11 deletion. To improve neurodevelopmental outcomes.

KEY DRIVERS

Identification of patients with TOF who require 22q11 screening

Increase knowledge of providers and patients about importance and benefit of genetic screening for 22q11 in patients with TOF

Appropriate testing and referral of patient requiring screening

Documentation of TOF and genetic testing results with results to carry through in problem list/patient history

INTERVENTIONS

Identify patients with TOF and determine if 22q11 testing has been performed prenataally or postnatally.

Implement site specific means of flagging/testing 22q11 in patient

Develop educational program for parents to understand importance of genetic screening for 22q11 deletion in patients with TOF and to increase knowledge of available resources

Develop educational program for pediatric cardiologists regarding need for 22q11 testing

Establish and implement clinical pathway tool and order set for patients with TOF to include genetic screening for 22q11 deletion and genetics consultation
**Smart Aim**

Increase screening for 22q11 deletion in patients with TOF to 100% at all QNet participating pediatric heart centers by December 31, 2017

**Global Aim**

To provide appropriate counseling, multidisciplinary care, and early intervention services for patients with 22q11 deletion. To improve neurodevelopmental outcomes.

**Key Drivers**

Identification of patients with TOF who require 22q11 screening

**Interventions**

- Identify patients with TOF and determine if 22q11 testing has been performed prenatally or postnatally.
- Implement site specific means of flagging/testing 22q11 in patients.
- Establish and implement clinical pathway tool and order set for patients with TOF to include genetic screening for 22q11 deletion and genetics consultation.
22q11 Screening in TOF: KEY DRIVER DIAGRAM

**SMART AIM**
Increase screening for 22q11 deletion in patients with TOF to 100% at all QNet participating pediatric heart centers by December 31, 2017

**GLOBAL AIM**
To provide appropriate counseling, multi-disciplinary care, and early intervention services for patients with 22q11 deletion. To improve neurodevelopmental outcomes.

**KEY DRIVERS**
Increase knowledge of providers and patients about importance and benefit of genetic screening for 22q11 in patients with TOF

**INTERVENTIONS**
Develop educational program for parents to understand importance of genetic screening for 22q11 deletion in patients with TOF and to increase knowledge of available resources.

Develop educational program for pediatric cardiologists regarding need for 22q11 testing.
22q11 Screening in TOF: KEY DRIVER DIAGRAM

SMART AIM
Increase screening for 22q11 deletion in patients with TOF to 100% at all QNet participating pediatric heart centers by December 31, 2017

GLOBAL AIM
To provide appropriate counseling, multidisciplinary care, and early intervention services for patients with 22q11 deletion. To improve neurodevelopmental outcomes.

KEY DRIVERS
Appropriate testing and referral of patient requiring screening

INTERVENTIONS
- Implement site specific means of flagging/testing 22q11 in patient
- Establish and implement clinical pathway tool and order set for patients with TOF to include genetic screening for 22q11 deletion and genetics consultation

Appropriate testing and referral of patient requiring screening

Establish and implement clinical pathway tool and order set for patients with TOF to include genetic screening for 22q11 deletion and genetics consultation
22q11 Screening in TOF: KEY DRIVER DIAGRAM

SMART AIM
Increase screening for 22q11 deletion in patients with TOF to 100% at all QNet participating pediatric heart centers by December 31, 2017

GLOBAL AIM
To provide appropriate counseling, multidisciplinary care, and early intervention services for patients with 22q11 deletion. To improve neurodevelopmental outcomes.

KEY DRIVERS
Documentation of TOF and genetic testing results with results to carry through in problem list/patient history

INTERVENTIONS
Implement site specific means of flagging/testing 22q11 in patient
Next Steps

- Early implementation of strategies at various centers
  - Assess successes
  - Assess hang-ups
- Talk to institution “F”!!!
- Re-strategize interventions
- Track changes in quarterly data
Thank You!